Literature DB >> 16983059

Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis.

Jérôme Filippi, Pierre-Marie Roger, Stéphane M Schneider, Jacques Durant, Jean-Philippe Breittmayer, Sylvia Benzaken, Alain Bernard, Pierre Dellamonica, Xavier Hébuterne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16983059     DOI： 10.1001/archinte.166.16.1783

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  4 in total

1.  Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?

Authors:  Jason J Emer
Journal:  J Clin Aesthet Dermatol       Date:  2009-04

Review 2.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

3.  Successful treatment of severe perianal Crohn's disease with infliximab in an HIV-positive patient.

Authors:  Maria Ana Rafael; Luís Carvalho Lourenço; Ana Maria Oliveira; Teresa Branco; Carla Carneiro; Ana Costa; Jorge Reis
Journal:  Clin J Gastroenterol       Date:  2019-05-20

Review 4.  Tumor necrosis factor blockade and the risk of viral infection.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.